Demonstrated to significantly reduce stroke compared to warfarin, Pradaxa is first new oral anticoagulant approved by the FDA in more than 50 years RIDGEFIELD, Conn., Oct. 19 /PRNewswire/ -- The U.S.

RIDGEFIELD, Conn., March 19, 2017 /PRNewswire/ -- Important new data from the RE-CIRCUIT® study show a better safety profile for Pradaxa® (dabigatran etexilate mesylate) compared to warfarin in atrial ...

INGELHEIM, Germany--(BUSINESS WIRE)--The RE-DUAL PCI™ trial explored anticoagulation with Pradaxa ® (dabigatran etexilate) dual therapy without aspirin in non-valvular atrial fibrillation (AF) ...

(HealthDay News) — In clinical practice, patients starting dabigatran therapy do not have significantly different rates of ischemic stroke or extracranial hemorrhage than those starting warfarin ...

The Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial compared the efficacy and safety of dabigatran (Pradax in Canada and Pradaxa in Europe), a new oral direct thrombin ...

In 2010, the blood thinner dabigatran (brand name Pradaxa) was approved by the U.S. Food and Drug Administration as a treatment option for people with atrial fibrillation. Dabigatran was at least as ...

Patients with atrial fibrillation who take the blood thinner dabigatran are at greater risk for major bleeding and gastrointestinal bleeding than those who take warfarin, according to a new study. The ...

RIDGEFIELD, Conn., July 21, 2011 /PRNewswire/ --Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) today announced that Pradaxa® (dabigatran etexilate mesylate) capsules has been added to hospital ...

Blockbuster blood-thinner Pradaxa will come under scrutiny again, it appears. The FDA announced last Friday that it has established a study to evaluate post-trial safety outcomes in blood-thinning ...

The Atrial Fibrillation Market in Brazil is Expected to Grow at a Rate of 31 Percent Annually over the Next Five Years Decision Resources, one of the world’s leading research and advisory firms for ...

“The results we have seen from RE-DUAL PCI™ are another great piece of evidence on the benefit Pradaxa ® can offer patients with atrial fibrillation and their treating physicians; a benefit which has ...